Consolidated Statements of Cash Flows (USD $) In Thousands | 9 Months Ended |
|---|
Sep. 30, 2011 | Sep. 30, 2010 |
|---|
| Operating activities | | |
| Net income | $ 82,108 | $ 69,443 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation | 7,071 | 6,732 |
| Amortization | 1,243 | 1,827 |
| Share-based compensation | 6,143 | 5,912 |
| Excess tax benefits from share-based compensation | (2,229) | (1,271) |
| Equity earnings in unconsolidated investments | (185) | (117) |
| Other | (3,892) | (7,673) |
| Changes in operating assets and liabilities, net of effects of acquisitions: | | |
| Receivables | (55,941) | (49,043) |
| Product inventories | 10,999 | 55,482 |
| Accounts payable | (49,542) | (55,586) |
| Other current assets and liabilities | 36,199 | 39,536 |
| Net cash provided by operating activities | 31,974 | 65,242 |
| Investing activities | | |
| Acquisition of businesses, net of cash acquired | (2,961) | (4,872) |
| Purchase of property and equipment, net of sale proceeds | (16,959) | (6,600) |
| Other investments | (177) | 0 |
| Net cash used in investing activities | (20,097) | (11,472) |
| Financing activities | | |
| Proceeds from revolving line of credit | 446,649 | 370,639 |
| Payments on revolving line of credit | (376,649) | (354,668) |
| Payments on long-term debt and other long-term liabilities | (145) | (36,160) |
| Payments of deferred acquisition consideration | (500) | (500) |
| Payments of deferred financing costs | 0 | (145) |
| Excess tax benefits from share-based compensation | 2,229 | 1,271 |
| Proceeds from stock issued under share-based compensation plans | 9,506 | 4,717 |
| Payments of cash dividends | (19,798) | (19,308) |
| Purchases of treasury stock | (62,842) | (1,534) |
| Net cash used in financing activities | (1,550) | (35,688) |
| Effect of exchange rate changes on cash and cash equivalents | 608 | (1,364) |
| Change in cash and cash equivalents | 10,935 | 16,718 |
| Cash and cash equivalents at beginning of period | 9,721 | 15,843 |
| Cash and cash equivalents at end of period | $ 20,656 | $ 32,561 |